InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
4
T+90 hit rate
10%
T+90 mean return
-15.4%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Sepp-Lorenzino Laura, Directeur Scientifique. Insider active across 2 companies, notably Intellia Therapeutics, Inc.. In total, 15 filings have been logged. Split: 0 buy · 4 sells. Total volume traded: €386k. Activity tracked since 4 August 2021. The latest transaction was disclosed on 3 January 2025 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations15 total
▼
8,966 shares@ US$12.186.7% of flowCommon StockSEC:0000950170-25-003002:0
3,500 sharesCommon StockSEC:0000950170-25-001232:0
49,220 shares0Common StockSEC:0001415889-24-015038:0
37,966 shares0Common StockSEC:0000950170-24-025907:0
▼
1,608 shares@ US$28.662.7% of flowCommon StockSEC:0000950170-24-003632:0
▼
5,532 shares@ US$29.469.4% of flowCommon StockSEC:0000950170-24-002514:0
3,500 sharesCommon StockSEC:0000950170-24-001210:0
29,938 shares0Common StockSEC:0001209191-23-015742:0
▼
2,508 shares@ US$37.215.6% of flowCommon StockSEC:0001209191-23-002433:0
3,500 sharesCommon StockSEC:0001209191-23-001498:0
3,500 sharesCommon StockSEC:0001209191-22-015976:0
◇
27,000 shares@ US$13.400.016% mcap25.5% of flowCommon StockSEC:0001209191-21-054321:0
◇
27,000 shares@ US$13.4019.3% of flowCommon StockSEC:0001209191-21-054321
◇
26,000 shares@ US$13.400.015% mcap24.5% of flowCommon StockSEC:0001209191-21-050228:0
◇
26,000 shares@ US$13.4018.5% of flowCommon StockSEC:0001209191-21-050228
15 of 15 declarations
About Sepp-Lorenzino Laura
Laura Sepp-Lorenzino is the Chief Scientific Officer at Intellia Therapeutics, Inc. She is responsible for leading scientific initiatives and research within the company. Laura Sepp-Lorenzino plays a key role in developing new therapies and scientific innovation. Her expertise in research is crucial for Intellia's mission.
